Introduction
In renal transplant recipients (RTxRs), a regimen containing calcineurin inhibitors (CNIs: cyclosporine [CsA] or tacrolimus [Tac] ), mycophenolate mofetil (MMF), and steroids is considered the current standard of care, yielding low rates of acute rejection and excellent shortto-medium-term graft survival (1, 2) . However, long-term CNI use increases the risk of complications, including nephrotoxicity, malignancies, and cardiovascular diseases (3) (4) (5) , impacting long-term graft survival. Thus, regimens enabling CNI reduction may be beneficial. Several studies suggest that an everolimus (EVR)-based immunosuppressive strategy to facilitate CNI reduction (particularly CsA) results in good renal function and low treated biopsy-proven acute rejection (tBPAR) and graft-loss rates (6) (7) (8) (9) . In the United States, EVR in combination with basiliximab, low-dose (L) CsA, and corticosteroids is currently indicated for the prophylaxis of organ rejection in adult RTxRs. EVR in combination with low-dose tacrolimus (LTac) has provided adequate immunosuppression in liver transplantation (10) . In recent years, >90% of adult RTxRs received Tac (11) , and Tac in conjunction with azathioprine or MMF is currently the only Tac-based regimen approved in the United States.
Two 6-month studies in the United States (12, 13 ) and a 12-month, open-label study (14) conducted outside the United States evaluating EVR+Tac-based regimens demonstrated that EVR facilitates Tac reduction while achieving good renal function and low BPAR and graft-loss rates, with acceptable safety profiles in renal transplantation. The efficacy and safety of the EVR+Tac regimen have hitherto not been evaluated in a large North-American cohort. This trial was conducted to assess efficacy and safety of EVR with low-dose Tac (EVR+LTac) versus MMF with standard-dose Tac (MMF+STac) regimen in de novo RTxRs from North America as a strategy for optimizing graft outcomes.
Methods

Study design
This was a 12-month, multicenter (50 American and 2 Canadian centers; Table S1 ), randomized, open-label, noninferiority trial (ClinicalTrials.gov identifier code: NCT01025817). Eligible patients were randomized (1:1), between January 2010 and February 2012, to the following treatment groups <24-h posttransplantation: Institutional review boards of each center approved the study protocol, and all patients provided written informed consent. The study was designed and implemented in accordance with International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use-Guideline for Good Clinical Practice (ICH-GCP) (15) , with applicable local regulations and ethical principles as outlined in the Declaration of Helsinki.
Study population
Patients aged 18-70 years, receiving a kidney from a deceased donor (including expanded criteria donor [ECD] and deceased donor after cardiac death [DCD] ) or living-unrelated or non-HLA identical living-related donor, were eligible for the study. Major exclusion criteria were cold ischemic time >30 h; ABO-incompatible or T-cell/B-cell cross-match positive transplants; recipients with platelet count <100 000/mm 3 , neutrophil count <1500/mm 3 , or white blood cell (WBC) <3000/mm 3 ; history of malignancy within past 2 years; human immunodeficiency virus, hepatitis B or C infections; or presence of any other systemic infections <30 days before transplantation.
Randomization and immunosuppression
Novartis Drug Supply Management generated a randomization list, using a validated system with a fixed-block design that automated treatmentarm randomization in the specified ratio. The randomization scheme was reviewed, approved, and locked by a member of the Biostatistics Quality Assurance Group. Investigators received treatment allocation cards with sequential randomization numbers and treatment group information. Scratch-off label of the treatment allocation card with the lowest randomization number was removed to reveal the treatment group. The card was filed with opening date and patient's source documents and was verified by the study monitor. 
Study objectives
The primary objective was to evaluate noninferiority of the composite efficacy failure rate (tBPAR/graft loss/death/loss to follow-up) at Month 12 between treatment groups (noninferiority margin: 10%). Key secondary objective was to compare renal function as estimated GFR (eGFR) calculated using the MDRD-4 formula (16) between the treatment groups at Month 12. Other secondary objectives were to compare incidences of CMV (viremia, syndrome, or disease), BK virus (BKV; viruria, viremia, or nephropathy), chronic kidney disease (CKD) with associated proteinuria, new-onset diabetes after transplantation (NODAT), AEs, and serious AEs (SAEs). Incidences of CMV and BKV infections were based on AEs, and viral titers were not prospectively assessed.
Statistical methods
Categorical variables were compared using chi-square tests. Continuous variables were compared using t-tests. All efficacy analyses were conducted in the full analysis set that included all randomized patients. EVR+LTac was considered noninferior to MMF+STac if the upper limit of 95% confidence interval (CI) of the difference between the composite efficacy failure rates adjusted for induction therapy was less than conservative noninferiority margin of 10%, derived using the conservative 95-95 approach (17) . In this approach, the control (induction+corticosteroid+ sTAC+MMF) and putative placebo (induction+corticosteroid+rTAC) effects were estimated using a meta-analysis of historical trials. Mixed-effect logistic regression model was used to estimate the contribution of each of the immunosuppressive drugs to the combination therapy event rate, assuming additive drug effects in a combination therapy in the log-odds scale. A 95% CI was calculated for the difference between the failure rates of placebo and control arms. The noninferiority margin was determined to be the lower limit of this CI. Alternatively, information about standard error of historical estimates of the control effect was used to derive a less-conservative noninferiority margin of 12% (18, 19 (20) were used to classify CKD stages. Safety analyses were performed in the safety population (patients who received at least one dose of study drug and had a postbaseline safety assessment). NODAT was defined as previously nondiabetic patients who required a glucose-lowering treatment for >30 days posttransplant or had random plasma glucose level ≥200 mg dL (11.1 mmol/L) with two fasting plasma glucose values ≥126 mg/dL (7 mmol/L). Incidences of wound complications with EVR+LTac versus MMF+STac throughout 12 months were reported descriptively. Effect of BMI, recipient age, induction agent, and history of diabetes on wound complications was also analyzed by logistic regression.
Sample size
Sample size was determined based on 80% power, assuming no difference in composite efficacy failure rates between treatment groups. A composite efficacy failure rate of 25% was assumed for each treatment group with a noninferiority limit difference of 10% with a one-sided significance level of 2.5%. Thus, a sample size of 590 randomized patients (295 per treatment group) was necessary (nQuery Advisor, Version 4.0, Statistical Solutions Ltd., Cork, Ireland).
Results
Patient disposition, demographics, and baseline characteristics In total, 613 patients were randomized to EVR+LTac (N = 309) or MMF+STac (N = 304) groups. Considering the updated noninferiority margin (11.2%), while the EVR+LTac group missed noninferiority by 0.2% in overall population, in the low-to-moderate risk and the per-protocol populations it met noninferiority versus MMF+STac.
Total Screened N = 738
Reasons for screening failure, n = 125 Did not meet diagnostic/severity criteria, n = 7 Intercurrent medical event, n = 9 Other, n = 60 Subject withdrew consent, n = 5 Unacceptable laboratory value (s), n = 22 Unacceptable past medical history/ concomitant diagnosis, n = 5 Unacceptable test procedure result (s), n = 2 Unacceptable use of excluded medications/ therapies, n = 14 Unknown, n = 1
Discontinued study medication, n = 105 (34.0%) Adverse events, n = 66 (21.4%) Unsatisfactory therapeutic effect, n = 7 (2.3%) Abnormal test procedure result(s), n = 4 (1.3%) Subject withdrew consent, n = 8 (2.6%) Administrative problems, n = 7 (2.3%) Protocol deviation, n = 9 (2.9%) Graft loss, n = 2 (0.6%) Death, n = 2 (0.6%)
Discontinued study medication, n = 72 (23.7%) Adverse events, n = 39 (12.8%) Abnormal laboratory value(s), n = 2 (0.7%) Subjects condition no longer required study drug, n = 1 (0.3%) Subject withdrew consent, n = 9 (3.0%) Loss to follow-up, n = 1 (0.3%) Administrative problems, n = 5 (1.6%) Protocol deviation, n = 8 (2.6%) Graft loss, n = 5 (1.6%) Death, n = 2 (0.7%) EVR+LTac, n = 309 Received study medication, n = 306 Did not receive study medication, n = 3 Subject withdrew consent, n = 3
MMF+STac, n = 304 Received study medication, n = 304 FAS, n = 309 (100%) Safety, n = 306 (99.0%) PPS, n = 250 (80.9%) FAS, n = 304 (100%) Safety, n = 304 (100%) PPS, n = 243 (79.9%) Figure 1 : Patients disposition. *In the EVR arm: one patient moved; one patient refused all medications and treatments due to steroid-induced psychosis; one patient discontinued care at the study center; one patient discontinued from the study due to worsening diarrhea; two patients voluntarily withdrew consent; and two patients withdrew consent prior to taking any study drug. **In the MMF arm: four patients did not wish to attend further study visits; two patients withdrew consent to enter follow-up; one patient withdrew consent due to conflict of job; one patient was noncompliant; one patient did not want to continue due to time constraints; one patient did not want to complete follow-up if there was no direct benefit for him; one patient discontinued due to increased somnolence; one patient discontinued due to mesothelioma of lung; one patient moved between US states; one patient cancelled the last appointment without rescheduling; one patient indicated that he would be followed by his primary care physician; and one patient withdrew consent without giving a specific reason. EVR, everolimus; FAS, full analysis set; LTac, low-dose tacrolimus; MMF, mycophenolate mofetil; PPS, per protocol set; STac, standard tacrolimus.
In a post-hoc analysis conducted in patients from normally exposing centers (excluding centers where >30% of EVR C 0 measured at <3 ng/mL), the noninferiority margin (10%) for the primary outcome was met (EVR+L- In the full analysis set, overall incidence of tBPAR was significantly higher in EVR+LTac versus MMF+STac group (59 [19.1%] vs. 34 [11.2%]; p < 0.05), although the majority of acute rejection episodes were of Banff IA (10.4% vs. 5.3%; Table 3 ). Of the tBPAR episodes in EVR+LTac group, 37.3% (n = 22/59) occurred within the first 2 weeks posttransplantation. Incidence of tBPAR was higher in the EVR+LTac versus MMF+STac in the low-to-moderate risk (18.3% vs. 11.4%) and the highrisk groups (20.8% vs. 10.6%). The K-M estimate of patients free-from-tBPAR ( Figure 3B) (Figure 3C) . ).
Renal function
In the full analysis set, eGFR was similar between treatment groups (EVR+LTac vs.
Incidence of proteinuria was similar in EVR+LTac versus
MMF+STac group by Month 12 ( Figure 5 ). Mean urine protein/creatinine ratio 12 months posttransplantation was similar with EVR+LTac versus MMF+STac (333.9 vs. 252.2 mg/g). incidence of CMV infection with EVR+LTac (vs. MMF+STac) was most pronounced in patients with D+/R− and D−/R+ serostatus, in patients without CMV prophylaxis (Table 5) , and in patients on rATG induction therapy (2.1% vs. 9.6%). BKV infection rate was comparable between EVR+LTac versus MMF+STac (11.1% vs. 12.5%; p = 0.62).
Malignancy: Overall incidences of malignancies were similar between the EVR+LTac and MMF+STac groups (10 [3.3%] vs. 15 [4.9%] ). Basal cell carcinoma was the most frequently reported malignancy.
Wound complications:
The most frequently (≥10%) reported wound complications were fluid collections adjacent to the transplant site, fluid leakage from the wound, and delayed or impaired transplant incision healing. Incidences of wound complication such as lymphocele, seroma, urinoma, hematoma, hernia, and dehiscence were comparable between the groups (Table 6) .
During the study, proportions of patients requiring surgical repair (7.2% vs. 5.6%; p = 0.51) or interventional radiology (4.6% vs. 4.3%; p = 1.00) were similar in EVR+LTac and MMF+STac groups. Based on logistic regression, history of diabetes was the only significant risk factor (odds ratio = 1.56, [1.04, 2.34], p = 0.03) associated with wound complication. More recipients in EVR+LTac (n = 111, 36.3%) versus MMF+STac (n = 95, 31.3%) groups had a history of diabetes mellitus. 
Discussion
In this study of RTxRs from North America, the noninferiority (10% margin) in composite efficacy failure rate for patients from underexposing centers (centers with >30% of EVR levels <3 ng/mL), tBPAR rate (EVR+LTac: 43.2% vs. MMF+STac: 17.1%) was higher than that of EVR+LTac in full analysis set. These findings suggest that achieving therapeutic EVR C 0 levels contributes to a immunosuppression comparable to that of the MMF+STac. Previously in the ASSET study, which compared EVR+low Tac (4-7 ng/mL) and EVR+very-low Tac (1.5-3 ng/mL), the starting dose of EVR was 1.5 mg b.i.d. and EVR target C 0 (3-8 ng/mL) were achieved at all time points. EVR-based Tac reduction resulted in good renal function and similar incidence of BPAR (EVR+low Tac vs. EVR+very-low Tac: 1.1% vs. 2.2%; p = 0.0138) from randomization to Month 12 (14) , further suggesting that initiating EVR at a higher dose (1.5 mg b.i.d.), to achieve the target therapeutic C 0 , may provide an optimal immunosuppression contributing to improved efficacy against acute rejection. This strategy is currently being evaluated in the ongoing TRANSFORM study (21) . Our study reported a significantly lower rate of graft loss and similar incidence of deaths in the EVR+LTac versus MMF+STac group.
One month posttransplantation, renal function improved in both treatment groups, and was maintained throughout the study period thereafter, with no statistically significant difference between groups at Month 12. The mean eGFR at Month 12 was similar for both groups and better than reported in previous studies with EVR+Lower-dose CNI (9, 14) . At Month 12, the incidence of proteinuria reported in the study was comparable between EVR+L-Tac and MMF+STac groups, and lower or consistent with previous reports on EVR+Lower-dose CNI (9, 14) .
The safety findings in this study were consistent with the known safety profiles of EVR, MMF, and Tac (9, 14, 22, 23) . However, there were more discontinuations due to AEs with EVR+LTac versus MMF+STac (22.2% vs. 14.5%), and conversely, more dose adjustments with MMF+STac than with EVR+LTac (34.6% vs. 55.9%).
MMF+Tac is an approved regimen, and transplant surgeons and nephrologists are familiar with performing dose adjustments to manage these AEs appropriately. Lack of familiarity with the use of EVR+Tac regimen could explain the increased discontinuation due to AEs.
Overall infection rates were comparable between treatment groups and consistent with previous findings in EVR+Lower-dose CNIs (9, 14, 24) . Wound complications, another common concern that needs critical monitoring posttransplantation, were comparable between the groups, and similar to previously reported pooled data in de novo RTxR (25, 26) . Although this study examined a 12-month duration only, malignancy incidence (neoplasms, benign, malignant, and unspecified) was comparable between EVR+LTac and MMF+STac groups.
Conclusions
Noninferiority (10%) of composite efficacy failure rate for EVR+LTac versus MMF+STac was not achieved due to a higher rate of acute rejection. EVR+LTac met noninferiority versus MMF+STac in the overall population considering the less-conservative noninferiority margin (12%) and in the low-to-moderate risk patients considering the original less-conservative (12%) and the revisedconservative noninferiority margin (11.2%). Despite higher rejection rates, EVR in combination with LTac, basiliximab, or rATG induction therapy and corticosteroids achieved significantly lower graft-loss rates, good renal function, and an acceptable safety profile. Many of the acute rejections were reported during the first 2 weeks of transplantation, and may be attributed to the suboptimal immunosuppression during the early weeks following renal transplantation. Further studies evaluating optimal immunosuppression for improved efficacy will aid appropriate dosing and target levels of EVR and LTac in RTxRs.
